These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25175016)

  • 1. Free fatty acid particles in protein formulations, part 1: microspectroscopic identification.
    Cao X; Fesinmeyer RM; Pierini CJ; Siska CC; Litowski JR; Brych S; Wen ZQ; Kleemann GR
    J Pharm Sci; 2015 Feb; 104(2):433-46. PubMed ID: 25175016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
    Tomlinson A; Demeule B; Lin B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.
    Schiefelbein L; Keller M; Weissmann F; Luber M; Bracher F; Friess W
    Eur J Pharm Biopharm; 2010 Nov; 76(3):342-50. PubMed ID: 20816956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
    Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
    Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
    Kerwin BA
    J Pharm Sci; 2008 Aug; 97(8):2924-35. PubMed ID: 17973307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Newly Identified Impurity in Polysorbate 80, the Long-Chain Ketone 12-Tricosanone, Forms Visible Particles in a Biopharmaceutical Drug Product.
    Hampl V; Guo X; Ehrenstrasser C; Viertler M; Rayner L; Campanelli G; Schipflinger R; Thewes K; Cerreti A; Boehm S; Sonderegger C
    J Pharm Sci; 2018 Jun; 107(6):1552-1561. PubMed ID: 29499279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
    Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surfactant Effects on Particle Generation in Antibody Formulations in Pre-filled Syringes.
    Gerhardt A; Mcumber AC; Nguyen BH; Lewus R; Schwartz DK; Carpenter JF; Randolph TW
    J Pharm Sci; 2015 Dec; 104(12):4056-4064. PubMed ID: 26413998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Fatty Acid Composition in Polysorbate 80 on the Stability of Therapeutic Protein Formulations.
    Pegues MA; Szczepanek K; Sheikh F; Thacker SG; Aryal B; Ghorab MK; Wolfgang S; Donnelly RP; Verthelyi D; Rao VA
    Pharm Res; 2021 Nov; 38(11):1961-1975. PubMed ID: 34845573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended Characterization and Impact of Visible Fatty Acid Particles - A Case Study With a mAb Product.
    Saggu M; Demeule B; Jiang L; Kammerer D; Nayak PK; Tai M; Xiao N; Tomlinson A
    J Pharm Sci; 2021 Mar; 110(3):1093-1102. PubMed ID: 33271136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.
    Li Y; Hewitt D; Lentz YK; Ji JA; Zhang TY; Zhang K
    Anal Chem; 2014 May; 86(10):5150-7. PubMed ID: 24749737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations.
    Labrenz SR
    J Pharm Sci; 2014 Aug; 103(8):2268-77. PubMed ID: 24942482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation.
    Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K
    J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.